December 3, 2021

Monoclonal Antibody Therapy Update

To:            Members of the LMH Health Medical Staff and Independent Practices.

From:       Dr. Christopher Brychel, Caitlin Johnston, APRN, Christina Lawrenz, RPh

LMH Health has been notified of a significant reduction in the amount of monoclonal antibody we are allocated.

Due to the sudden interruption in the monoclonal supply chain, BMI and symptom duration criteria have changed to ensure greatest benefit for our highest risk patients is prioritized. Until further notice, the following monoclonal criteria changes will apply:

• BMI > 35 (previously > 25)
• Symptom duration <7 days (previously <10 days)
• Remainder of criteria unchanged

We will return to the selection criteria previously attached to the November 30 communication when resources allow. We will be discussing how to proceed forward once we have projections for our December 6 and December 13 allocations. Additionally, we will review triage options within the Ethics committee in the event of further scarcity. We apologize for any confusion, however, the significant reduction in allocation was not anticipated despite close monitoring and communications with KDHE. Given the concomitant uptick in COVID positive patients, direct ordering of monoclonals will be delayed until December 13 and we will maintain our current referral process in the interim. Updates will be communicated as soon possible and we recommend closely monitoring your LMH Health communications platform. 

https://www.phe.gov/emergency/events/COVID19/therapeutics/distribution/Pages/data-tables.aspx

For any clarifying questions, contact Dr. Christopher Brychel, Caitlin Johnston APRN, or Christina Lawrenz RPh.

Sincerely,

Chris Brychel, M.D.

Caitlin Johnston, APRN

Christina Lawrenz, RPh